Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (886)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02749136 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | unknown | Phase 2 | 116 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2019 | clinicaltrials |
| NCT04115618 | SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | unknown | Phase 2 | 60 | Wakayama Medical UniversityOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02854839 | A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma | completed | Phase 2 | 78 | GC Cell CorporationINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01825824 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm | unknown | Phase 2 | 54 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01850368 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion | completed | Phase 2 | 35 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01850667 | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | completed | Phase 2 | 74 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)(Panc-Durval+RT) | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Sep 12, 2019 | clinicaltrials |
| NCT03008343 | Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT03516071 | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | completed | Phase 2 | 90 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04077983 | Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 4, 2019 | clinicaltrials |
| NCT03042182 | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma(cholangio) | unknown | Phase 1 / Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03939975 | Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC | completed | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT04054518 | Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma(DESC) | unknown | Phase 2 | 22 | Tiago BiachiOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT02108145 | Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 70 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT03944252 | Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)(CARACAS) | unknown | Phase 2 | 54 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jul 26, 2019 | clinicaltrials |
| NCT03185988 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | unknown | Phase 2 | 100 | Shen LinOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Dec 10, 2019source: clinicaltrials